This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ARNA Arena Pharmaceuticals (ARNA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Arena Pharmaceuticals Stock (NASDAQ:ARNA) 30 days 90 days 365 days Advanced Chart Get Arena Pharmaceuticals alerts:Sign Up Key Stats Today's Range$99.99▼$99.9950-Day Range$93.13▼$99.9952-Week Range$45.50▼$100.00Volume107 shsAverage Volume1.56 million shsMarket Capitalization$6.17 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc. Read More Receive ARNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARNA Stock News HeadlinesNeuvivo makes bid to enter ALS arena with immunotherapy candidateOctober 7, 2024 | msn.comArwana Citramulia Tbk (ARNA)August 31, 2023 | uk.investing.comBanks aren’t ready for this altcoin—are you?In crypto, timing is everything. By the time the masses catch wind of this, the biggest gains could be ancient history. Are you ready to potentially change your financial future forever?July 2 at 2:00 AM | Crypto 101 Media (Ad)MLS club places Bruce Arena on leave over probe into 'allegations of insensitive and inappropriate remarks'August 21, 2023 | foxnews.comRNA startup launches with $300M, Merck partnershipMay 23, 2023 | bizjournals.comLongboard Pharmaceuticals: Undervalued Arena Spin-Out Has 2 Data Catalysts Due In 2023May 23, 2023 | seekingalpha.comPfizer earnings and revenue top expectations despite Covid vaccine sales declineMay 6, 2023 | cnbc.comArna L. DavidsonApril 25, 2023 | health.usnews.comSee More Headlines ARNA Stock Analysis - Frequently Asked Questions How were Arena Pharmaceuticals' earnings last quarter? Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($3.21) EPS for the quarter, missing analysts' consensus estimates of ($2.53) by $0.68. When did Arena Pharmaceuticals' stock split? Arena Pharmaceuticals shares reverse split on Monday, June 19th 2017.The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Arena Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Meta Platforms (META), Cytokinetics (CYTK), Micron Technology (MU), Bristol Myers Squibb (BMY) and Canopy Growth (CGC). Company Calendar Last Earnings11/04/2021Today7/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ARNA CIK1080709 Webwww.arenapharm.com Phone(858) 453-7200Fax858-453-7210Employees448Year Founded1977Profitability EPS (Trailing Twelve Months)($10.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$616.43 million Net MarginsN/A Pretax Margin-1,141,542.63% Return on Equity-69.83% Return on Assets-62.35% Debt Debt-to-Equity Ratio0.05 Current Ratio8.59 Quick Ratio8.59 Sales & Book Value Annual Sales$50 thousand Price / Sales123,305.67 Cash FlowN/A Price / Cash FlowN/A Book Value$10.94 per share Price / Book9.14Miscellaneous Outstanding Shares61,659,000Free Float60,173,000Market Cap$6.17 billion OptionableOptionable Beta0.55 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:ARNA) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Pentagon just made a National Security move...This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.......Stansberry Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arena Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arena Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.